OMEROS CORP (OMER)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for OMER
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| OMER | Director; Chair | 72 | ["served as Executive Vice President of the Allen Institute for Immunology","35-year career at Eli Lilly and Company","senior vice president of biotechnology and immunology research","advanced over 100 molecules into clinical development","serves on the University of Michigan Technology Transfer National Advisory Board","advisor to Lilly Ventures","member of the Board of Directors of Tentarix Biotherapeutics LP","scientific advisor to a number of biotechnology and immunology companies","earned B.S. in microbiology from the University of Michigan","Ph.D. in microbiology-immunology from the University of Minnesota","postdoctoral studies in Molecular Immunology at Scripps Research"] | ["Scientific","AUDIT COMMITTEE","COMPENSATION COMMITTEE","NOMINATING AND GOVERNANCE COMMITTEE","Scientific Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Thomas F. Bumol, Ph.D., has served on our board of directors since February 2019 and as chair of our scientific committee since September 2019. Dr. Bumol served as Executive Vice President of the Allen Institute for Immunology in Seattle, Washington, from March 2018 until August 2022. Dr. Bumol joined the Allen Institute following a 35-year career at Eli Lilly and Company. Dr. Bumol held various positions at Eli Lilly from 1982 until his retirement in December 2017. He was most recently the senior vice president of biotechnology and immunology research and the site head of Eli Lilly s Biotechnology Center in San Diego, California. While at Eli Lilly, Dr. Bumol s teams and collaborators advanced over 100 molecules into clinical development, including TRULICITY (dulaglutide), TALTZ (ixekizumab), EMGALITY (galcanezumab) and mirikizumab. Through strategic alliances, he and his teams also helped develop and support REOPRO (abciximab) with Centocor Inc. (n/k/a Janssen Pharmaceutical Cos.) as well as OLUMIANT (baricitinib) with Incyte Corporation. Dr. Bumol serves on the University of Michigan Technology Transfer National Advisory Board and as an advisor to Lilly Ventures. He is a member of the Board of Directors of Tentarix Biotherapeutics LP, a private biotechnology company, and serves as a scientific advisor to a number of biotechnology and immunology companies. Dr. Bumol earned his B.S. degree in microbiology from the University of Michigan and his Ph.D. in microbiology-immunology from the University of Minnesota. He completed postdoctoral studies through a fellowship in the Department of Molecular Immunology at Scripps Research in La Jolla, California. Dr. Bumol s qualifications to serve on the board of directors include his scientific expertise in drug discovery and development and experience in strategic partnering and other collaborations within the life sciences and pharmaceutical industries.